pl-6983 pl-6983 pl-6983 is a synthetic peptide and selective mc4 receptor agonist which is under development by palatin technologies for the treatment of female sexual dysfunction and erectile dysfunction. it was developed as a successor to/replacement of bremelanotide (pt-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials. relative to bremelanotide, pl-6983 produces significantly lower increases in blood pressure in animal models. the drug has reportedly been in pre-clinical development for all medical indications since 2008. palatin has stated that "we are focusing development efforts on bremelanotide for , but are continuing evaluation of pl-6983." the chemical structure of pl-6983 has yet to be made public. pl-6983clinical dataroutes ofadministrationsubcutaneous injectionidentifierscas number1966957-74-3